In conclusion, we found that the cancer-related CNVs of CEP63, FOSL2 and PAQR6 were competent in evaluating recurrence or progression risk for BC patients and may be used for the risk group stratifications in the future. The gene discussed is PAQR6; the disease is breast cancer.